Received Nov 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | LA |
pain at the injection site starting two weeks after the vaccine; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 75-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received on an unknown date). Concurrent medical conditions included underweight (Underweight). Concomitant products included appetite stimulants. In SEP-2025, the patient received the 2nd dose of Shingrix (left deltoid). On an unknown date, 2 weeks after receiving Shingrix, the patient experienced injection site pain (Verbatim: pain at the injection site starting two weeks after the vaccine). The outcome of the injection site pain was resolving. It was unknown if the reporter considered the injection site pain to be related to Shingrix. It was unknown if the company considered the injection site pain to be related to Shingrix. Additional Information: GSK Receipt date: 11-NOV-2025 The patient states he received his second shingles vaccine sometime in the middle of September 2025 in his left deltoid. The reporter states he had pain at the injection site starting two weeks after the vaccine. The pain has improved but is ongoing when sleeping on left side. The batch number was not provided upon follow up with the reporter
Underweight (Underweight)
APPETITE STIMULANTS